Efficacy of maintenance olaparib plus bevacizumab according to clinical risk in patients with newly diagnosed, advanced ovarian cancer in the phase III PAOLA-1/ENGOT-ov25 trial

•Patients with newly diagnosed, advanced ovarian cancer were classified by clinical risk and according to biomarker status.•Higher risk: stage III with upfront surgery and residual disease or neoadjuvant chemotherapy, or stage IV.•Lower risk: stage III with upfront surgery and no residual disease.•Olaparib plus bevacizumab provided a progression-free survival benefit over bevacizumab in higher- and lower-risk patients.•A substantial benefit was seen in higher- and lower-risk HRD-positive patients.